• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Optical Methods for Tumor Treatment and Early Diagnosis: Mechanisms and Techniques >Contrast-agent-enhanced magnetic resonance imaging: early detection of neoplastic lesions of the CNS
【24h】

Contrast-agent-enhanced magnetic resonance imaging: early detection of neoplastic lesions of the CNS

机译：造影剂增强磁共振成像：中枢神经系统肿瘤性病变的早期发现

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Even though the intrinsic soft tissue contrast sensitivity of magnetic resonance imaging (MRI) affords excellent visualization of anatomic detail, certain pathologic processes may be diagnosed earlier with the administration of a contrast-enhancing agent. At present there is one agent, gadopentetate dimeglumine, GdDTPA, that has received FDA approval for use in the MR scanning of the brain and spine in human patients. This paramagnetic chelate distributes throughout the extracellular fluid space as dictated by capillary permeability so that abnormal vascularity and sites of blood-CNS barrier breakdown are highlighted. Primary neoplastic disease, metastases, meningeal extension, residual and recurrent tumor have been found to be better distinguished in MR images acquired after administration of GdDTPA. Routine administration of GdDTPA for cranial imaging has resulted in the discovery of otherwise occult lesions in approximately 3% of patients. Although the clinical utility and high therapeutic safety index of the first approved magnetic resonance contrast agent, GdDTPA, have been well established, other contrast agents, having different physical, chemical and biological properties, may offer improved sensitivity and bio-specificity. Agents currently being evaluated in vivo include: low osmolal paramagnetic chelates, superparamagnetic particles, metalloporphyrins, liposome encapsulated agents, perfluorocarbons, intravascular macromolecular chelate complexes and labeled monoclonal antibodies. Concurrent with advances in the development of new compounds, innovations in scanning hardware, pulse sequence design and image post-processing are helping to extend the efficacy of contrast media. Additional clinical experience will indicate which contrast agents and which MR techniques can best facilitate the early detection of specific neoplastic lesions.!
机译：摘要：尽管磁共振成像（MRI）固有的软组织对比敏感度可提供出色的解剖学细节可视化，但使用对比增强剂可以更早地诊断出某些病理过程。目前，有一种药物，g戊二酸二聚丁二胺，GdDTPA，已获得FDA批准，可用于人类患者大脑和脊柱的MR扫描。这种顺磁性螯合物由毛细血管渗透性决定，分布在整个细胞外液空间中，因此突出了异常血管和血液中枢神经系统屏障破坏的部位。已发现在施用GdDTPA后获得的MR图像中可以更好地区分原发性肿瘤疾病，转移，脑膜扩展，残留和复发性肿瘤。常规给予GdDTPA进行颅骨成像已导致大约3％的患者发现了隐匿性病变。尽管已经很好地建立了首个批准的磁共振造影剂GdDTPA的临床实用性和较高的治疗安全性指标，但是具有不同物理，化学和生物学特性的其他造影剂可以提供更高的敏感性和生物特异性。当前正在体内评估的药物包括：低渗透压的顺磁性螯合物，超顺磁性颗粒，金属卟啉，脂质体包裹的药物，全氟化碳，血管内大分子螯合物和标记的单克隆抗体。在开发新化合物的同时，扫描硬件，脉冲序列设计和图像后处理方面的创新正在帮助扩展造影剂的功效。其他临床经验将表明哪种造影剂和哪种MR技术可以最好地促进早期发现特定的肿瘤性病变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号